From the expression patterns of these genes, we observed that lineage-reprogramming treatment decreased the expression of tumor proliferation-associated genes such as CCND1, CCNE1, E2F1, FOXM1, MYBL2, TOP2A, BUB1, and PLK121,22 (Figure 2B, D-H), and increased the expression of genes associated with hepatocytic fate (ALB, ACCS2, AKR1C1, HMGCS1, and SCD) 23,24 (Figure 2B, I-K). The gene discussed is MYBL2; the disease is neoplasm.